- Home
- IMCR vs ECAT Comparison
IMCR vs ECAT Comparison
Compare IMCR & ECAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- ECAT
- Stock Information
- Founded
- IMCR 2008
- ECAT 2021
- Country
- IMCR United Kingdom
- ECAT United States
- Employees
- IMCR N/A
- ECAT N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- ECAT Trusts Except Educational Religious and Charitable
- Sector
- IMCR Health Care
- ECAT Finance
- Exchange
- IMCR Nasdaq
- ECAT Nasdaq
- Market Cap
- IMCR 1.5B
- ECAT 1.7B
- IPO Year
- IMCR 2021
- ECAT N/A
- Fundamental
- Price
- IMCR $32.77
- ECAT $16.26
- Analyst Decision
- IMCR Buy
- ECAT
- Analyst Count
- IMCR 10
- ECAT 0
- Target Price
- IMCR $58.13
- ECAT N/A
- AVG Volume (30 Days)
- IMCR 445.1K
- ECAT 278.6K
- Earning Date
- IMCR 08-07-2025
- ECAT 01-01-0001
- Dividend Yield
- IMCR N/A
- ECAT 9.20%
- EPS Growth
- IMCR N/A
- ECAT N/A
- EPS
- IMCR N/A
- ECAT 2.39
- Revenue
- IMCR $333,581,000.00
- ECAT N/A
- Revenue This Year
- IMCR $26.82
- ECAT N/A
- Revenue Next Year
- IMCR $8.15
- ECAT N/A
- P/E Ratio
- IMCR N/A
- ECAT $7.15
- Revenue Growth
- IMCR 25.75
- ECAT N/A
- 52 Week Low
- IMCR $23.15
- ECAT $14.02
- 52 Week High
- IMCR $41.54
- ECAT $17.30
- Technical
- Relative Strength Index (RSI)
- IMCR 45.73
- ECAT 56.22
- Support Level
- IMCR $30.76
- ECAT $15.52
- Resistance Level
- IMCR $32.55
- ECAT $16.14
- Average True Range (ATR)
- IMCR 1.39
- ECAT 0.18
- MACD
- IMCR -0.41
- ECAT 0.00
- Stochastic Oscillator
- IMCR 19.09
- ECAT 59.30
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.